Rallybio Corporation reported its financial results for the first quarter of 2026, revealing a net loss of $8.3 million, a decrease from the $9.4 million loss recorded in the same period of 2025. The company maintained collaboration and license revenue at $212,000 for both quarters, indicating no growth in this area. Operating expenses fell to $8.9 million from $9.9 million year-over-year, primarily due to a significant reduction in research and development costs, which dropped from $5.7 million to $2.9 million. This decrease was largely attributed to the discontinuation of the RLYB212 program, which had previously incurred substantial development costs.
In terms of operational changes, Rallybio has made strategic decisions impacting its product pipeline. The company completed a confirmatory pharmacokinetic and pharmacodynamic study of its lead program, RLYB116, in early 2026, which demonstrated improved tolerability and sustained inhibition of terminal complement. However, the company also announced the termination of its merger agreement with Candid Therapeutics in May 2026, resulting in a $50 million termination fee. This fee, along with a reimbursement of $0.4 million for expenses, contributed to the company's liquidity position, which stood at $46.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Rallybio's operational metrics reflect a focus on efficiency, with a reduction in employee headcount contributing to lower general and administrative expenses, which increased to $6.1 million from $4.2 million due to legal and professional fees associated with the terminated merger. The company reported a weighted average of 5.7 million shares outstanding, with a basic net loss per share of $1.46, an improvement from $1.69 in the prior year. The company continues to rely on equity financing for its operations, having raised approximately $182.5 million since inception, with no products currently approved for sale.
Looking ahead, Rallybio anticipates that its existing cash reserves will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for substantial additional capital to support the development and commercialization of its product candidates. The management's forward-looking statements highlight the ongoing challenges in clinical development and the competitive landscape, emphasizing the importance of strategic collaborations and potential licensing agreements to enhance its market position.
About Rallybio Corp
Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its pipeline includes product candidates targeting maternal-fetal blood disorders, complement dysregulation, hematology, and metabolic conditions. The company leverages scientific expertise, innovative drug design, and strategic collaborations to create transformative, patient-friendly treatments with high unmet medical needs, aiming to improve outcomes for underserved patient populations worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.